KCNJ11 and type 2 diabetes mellitus: Second, in KCNJ11 permanent neonatal diabetes, high-dose sulfonylureas facilitate the response to alternative pathway stimuli and do not directly stimulate insulin secretion as in type 2 diabetes.6